Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

507
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
507
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

313
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
313
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

344
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
344
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

338
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
338
Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

424
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
424
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

1.1K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Dataset on hydration, microstructure, mechanical performance and environmental impacts of Portland cement incorporating waste-derived ferrous sulfate.

Data in brief·2026
Same author

Achieving cell-type-specific bioorthogonal chemistry using enzyme-activated caged tetrazines.

Nature chemical biology·2026
Same author

A Longitudinal Assessment for Continuing Certification of Anesthesiologists: Utilization, Performance, and Perception of MOCA Minute.

Anesthesiology·2026
Same author

Breaking the membrane heredity paradox through de novo protocell formation.

Nature communications·2026
Same author

Tooth Loss and Uncontrolled Diabetes Among Korean Adults With Type 2 Diabetes: Insights From the Korea National Health and Nutrition Examination Survey (KNHANES) 2014-2018.

Clinical and experimental dental research·2026
Same author

<i>β</i>-Sheet Structures Enhance Aggregation-Induced Emission Signals in Peptide-Based Coacervates.

Chemistry of materials : a publication of the American Chemical Society·2026
Same journal

Recent progress in catalytic asymmetric synthesis of triarylmethanes.

Chemical science·2026
Same journal

GFP chromophore photophysics: ultrafast dynamics and hot ground state cooling in the neutral form.

Chemical science·2026
Same journal

Large Stokes shift fluorophores from <i>meta</i>-substituted zwitterions.

Chemical science·2026
Same journal

<i>In situ</i> glycosylation-directed H-aggregation of Type I photosensitizers for synergistic biofilm eradication and promoting diabetic wound healing.

Chemical science·2026
Same journal

Substituent engineering of dynamic covalent bonds enables simultaneous enhancement of performance and recyclability.

Chemical science·2026
Same journal

Visible-light-enabled three-component carboamidation of alkenes with aryl thianthrenium salts.

Chemical science·2026
See all related articles

Related Experiment Video

Updated: Nov 1, 2025

Lipid Exchange Assay in Living Cells
08:59

Lipid Exchange Assay in Living Cells

Published on: March 21, 2025

765

Lipase mimetic cyclodextrins.

Youngjun Lee1, Neal K Devaraj1

  • 1Department of Chemistry and Biochemistry, University of California San Diego, 9500 Gilman Drive La Jolla CA 92093 USA ndevaraj@ucsd.edu.

Chemical Science
|June 24, 2021
PubMed
Summary
This summary is machine-generated.

Researchers developed a cyclodextrin-based molecular device for selective glycerophospholipid (GPL) hydrolysis. This biomimetic tool can detect and break down specific lyso-GPLs, paving the way for lipid-related process manipulation.

More Related Videos

An In Ovo Model for Testing Insulin-mimetic Compounds
06:09

An In Ovo Model for Testing Insulin-mimetic Compounds

Published on: April 23, 2018

10.8K
Defining Substrate Specificities for Lipase and Phospholipase Candidates
08:59

Defining Substrate Specificities for Lipase and Phospholipase Candidates

Published on: November 23, 2016

15.2K

Related Experiment Videos

Last Updated: Nov 1, 2025

Lipid Exchange Assay in Living Cells
08:59

Lipid Exchange Assay in Living Cells

Published on: March 21, 2025

765
An In Ovo Model for Testing Insulin-mimetic Compounds
06:09

An In Ovo Model for Testing Insulin-mimetic Compounds

Published on: April 23, 2018

10.8K
Defining Substrate Specificities for Lipase and Phospholipase Candidates
08:59

Defining Substrate Specificities for Lipase and Phospholipase Candidates

Published on: November 23, 2016

15.2K

Area of Science:

  • Biochemistry
  • Chemical Biology
  • Biomaterials Science

Background:

  • Glycerophospholipids (GPLs) are vital cellular components involved in membrane structure and cell signaling.
  • The structural diversity and hydrophobicity of GPLs pose challenges for developing selective detection and manipulation tools.
  • Existing methods struggle to specifically target and modify individual GPL species within complex biological environments.

Purpose of the Study:

  • To engineer a biomimetic molecular device capable of selectively hydrolyzing specific glycerophospholipids (GPLs).
  • To investigate the host-guest chemistry of cyclodextrins for targeted lipid interactions.
  • To lay the groundwork for synthetic scaffolds that can modulate GPL-related biological processes.

Main Methods:

  • Utilized host-guest chemistry principles with chemically modified α-cyclodextrins.
  • Engineered an α-cyclodextrin scaffold bearing amine functional groups.
  • Tested the hydrolysis of various GPLs, including lyso-GPLs, under physiologically relevant conditions.

Main Results:

  • The engineered cyclodextrin selectively hydrolyzed lyso-glycerophospholipids (lyso-GPLs), producing free fatty acids.
  • Hydrolysis demonstrated preferential reaction with lyso-GPLs within a mixture of GPL species.
  • The efficiency of GPL hydrolysis was found to be dependent on the specific chemical structure of the lyso-GPL.

Conclusions:

  • A novel molecular device based on cyclodextrin chemistry can selectively hydrolyze specific GPLs.
  • This engineered scaffold offers a promising approach for targeted manipulation of lipid-related biological functions.
  • The findings support the development of advanced biomimetic tools for controlling cellular processes involving lipids.